Site Editor

William J. Gradishar, MD, FACP, FASCO


Javier Cortés, MD, PhD, on Chemotherapy De-escalation in HER2-Positive Early Breast Cancer: Practical Considerations From the PHERGain Trial Results

Posted: Tuesday, August 22, 2023

Javier Cortés, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discusses phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the patients treated with trastuzumab and pertuzumab alone, the 3-year invasive disease–free survival rate was 98.8%, with no distant metastases. But how practical is this approach for institutions that lack the appropriate PET technology?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.